Navigation Links
Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine
Date:4/16/2014

HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). The data demonstrate robust antibody and T cell responses and evidence of clinical benefit in patients with very advanced cancers and suggest that CDX-1401 may predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. CDX-1401 is an off-the-shelf vaccine consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The vaccine is designed to activate the patient's immune system against cancers that express the tumor marker NY-ESO-1. While the function of NY-ESO-1 continues to be explored, references in the literature suggest that its expression might reflect the acquisition of properties that cancers find useful, such as immortality, self-renewal, migratory ability and the capacity to invade.

The Phase 1 study of CDX-1401 is the first clinical study to demonstrate that an off-the-shelf vaccine that targets dendritic cells in vivo through DEC-205 can safely lead to robust humoral and cellular immunityovercoming a significant challenge in the development of protein based vaccines. Targeting protein antigens to the DEC-205 receptor on dendritic cells was pioneered by the late Ralph Steinman, MD, a member of Celldex's Scientific Advisory Board. Dr. Steinman received the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. This now-proven ability to target proteins, like NY-ESO-1, to dendritic cells to generate potent immune responses specific to these proteins represents a promising approach for the next generation of vaccines against pathogens and cancer.

"CDX-1401 offers a novel, well-tolerated and practical a
'/>"/>

Contact: Sarah Cavanaugh
scavanaugh@celldex.com
508-864-8337
Celldex Therapeutics
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... At the annual National League ... San Antonio, esteemed experts and thought leaders will ... in the way of successful organizational performance: resistance, ... faculty development opportunity is made possible through the ... to assist nurse educators to advance to leadership ...
(Date:12/21/2014)... In this report, the global powered ... product, and application. The market, by power source, ... By product, the market covers the handpieces; power ... market is further subdivided into drills, saws, reamers, ... shavers, wire/pin drivers, and others. Moreover, the power ...
(Date:12/21/2014)... Weddingshe.com, an outstanding online supplier of wedding dresses ... new selection of Cocktail Dresses for the winter 2014. ... newest fashion trends. , “We take pride ... . All of them are offered at greatly discounted ... every effort to offer a nice shopping experience for ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Khanna Vision ... a guest at the Aspen Helicopters holiday event for ... a Santa with sleigh, flown by an aspen helicopter ... invisible; only Santa with sleigh was visible.(please see accompanying ... and night. Dr.Khanna has helped many pilots with Pi ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 AngelWeddingDress.com’s new ... There is a total of 1,000 new designs in ... the coming spring 2015. , AngelWeddingDress.com promises ... female shoppers with wardrobe essentials while many fashion trends ... problems, the customer service team at AngelWeddingDress.com is ready ...
Breaking Medicine News(10 mins):Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2
... results across MDS, TORONTO, Sept. 6 /PRNewswire-FirstCall/ ... providing products and services to the global life ... For the quarter,MDS reported revenues of $321 million, ... from continuing operations of $0.07. Adjusted EBITDA,rose to ...
... product a proven treatment -, BELLEVILLE, ON, ... BNC), a research-based, technology-driven Canadian,biopharmaceutical company, today announced ... Australia in order to be able to respond ... continent,s equine influenza outbreak.,The outbreak began in August, ...
... N.Y., Sept. 6 /PRNewswire/, Who: Breast Cancer patients, survivors and ... (a breast cancer support center) on Thursday, September 6, What: ... ... wheels to encourage them to Keep ... to give cancer patients, survivors and caregivers a much needed ...
... Fairbank Farms, a national,ground beef producer, is ... Beef Patties. The ground beef patties, sold fresh,under ... consumers in New,England on Wednesday September 5, 2007 ... of caution, the product has been removed from ...
... Va., Sept. 5 AMERIGROUP,Corporation (NYSE: AGP ) ... Corporation have approved the sale of its assets,including TLC ... subject to regulatory approval by the State of Tennessee. ... of 2007. TLC Family Care Health Plan serves ...
... YORK, Sept. 5 Belfast Merger Co., a,wholly owned ... the expiration date for its cash tender offer for ... Inc. (Nasdaq: DADE ). The,tender offer has been ... September 26, 2007. The tender offer is being made ...
Cached Medicine News:Health News:MDS Reports Third Quarter 2007 Results 2Health News:MDS Reports Third Quarter 2007 Results 3Health News:MDS Reports Third Quarter 2007 Results 4Health News:MDS Reports Third Quarter 2007 Results 5Health News:MDS Reports Third Quarter 2007 Results 6Health News:MDS Reports Third Quarter 2007 Results 7Health News:MDS Reports Third Quarter 2007 Results 8Health News:MDS Reports Third Quarter 2007 Results 9Health News:MDS Reports Third Quarter 2007 Results 10Health News:MDS Reports Third Quarter 2007 Results 11Health News:MDS Reports Third Quarter 2007 Results 12Health News:MDS Reports Third Quarter 2007 Results 13Health News:MDS Reports Third Quarter 2007 Results 14Health News:MDS Reports Third Quarter 2007 Results 15Health News:MDS Reports Third Quarter 2007 Results 16Health News:MDS Reports Third Quarter 2007 Results 17Health News:MDS Reports Third Quarter 2007 Results 18Health News:MDS Reports Third Quarter 2007 Results 19Health News:MDS Reports Third Quarter 2007 Results 20Health News:MDS Reports Third Quarter 2007 Results 21Health News:MDS Reports Third Quarter 2007 Results 22Health News:MDS Reports Third Quarter 2007 Results 23Health News:MDS Reports Third Quarter 2007 Results 24Health News:MDS Reports Third Quarter 2007 Results 25Health News:MDS Reports Third Quarter 2007 Results 26Health News:MDS Reports Third Quarter 2007 Results 27Health News:MDS Reports Third Quarter 2007 Results 28Health News:MDS Reports Third Quarter 2007 Results 29Health News:MDS Reports Third Quarter 2007 Results 30Health News:MDS Reports Third Quarter 2007 Results 31Health News:MDS Reports Third Quarter 2007 Results 32Health News:MDS Reports Third Quarter 2007 Results 33Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R) 2
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)... Dec. 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... completion of enrollment in its first Phase 2a ... observations confirmed the 1-month findings that were reported ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
Icefire has ice crystals on the top of a cool blue iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Maumenee vitreous aspirating cannula, 18 gauge....
Medicine Products: